2023
Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer
Jalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.Peer-Reviewed Original ResearchConceptsOligometastatic prostate cancerCytoreductive radical prostatectomyMetastatic prostate cancerProstate cancerLocal therapyRadiation therapySystemic therapyClinical trialsDe novo metastatic prostate cancerProgression-free survivalWidespread metastatic diseaseStandard of careRecent FindingsTo dateClinician decision makingCytoreductive prostatectomySystemic chemotherapyMetastatic diseaseWidespread metastasesRetrospective studyRadical prostatectomyEarly treatmentLocal treatmentTreatment selectionTherapyPatients
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatients
2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy